Prevalence of multi-drug resistant tuberculosis in Karachi, Pakistan: identification of at risk groups

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 104, Issue 8, 2010, Pages 511-517

  Ejaz, Muslima ^a   Siddiqui, Amna Rehana ^a   Rafiq, Yasraba ^a   Malik, Faisal ^a   Channa, Abid ^a   Mangi, Rafique ^b   Habib, Faiza ^a   Hasan, Rumina ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b Marium Manzil Saddar   (Pakistan)

Author keywords

Drug resistance; Pakistan; Risk factors for Multidrug resistance; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG SENSITIVITY; ETHNICITY; FEMALE; HIGH RISK POPULATION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PAKISTAN; PREVALENCE; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PAKISTAN; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 77954540968     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2010.03.005     Document Type: Article

References (38)

1. Dye C., Espinal M.A., Watt C.J., Mbiaga C., Williams B.G. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002, 185:1197-1202.
2. WHO/IUATLD. Global Project on Anti-Tuberculosis Drug Resistance in the world. Prevalence and Trends. Anti-tuberculosis Drug Resistance in the World. Report No 2. WHO/CDS/TB 2000.278. Geneva: World Health Organization; 2000.
3. WHO/IUATLD. Global Project on Anti-Tuberculosis Drug Resistance Surveillance System 2002-2007. Anti-Tuberculosis Drug Resistance in the World. Fourth Global Report. WHO/HTM/2008-394.
4. WHO. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2008. Geneva: World Health Organization; 2008 WHO/HTM/TB/2008.393.
5. Lambregts-van Weezenbeek C.S., Veen J. Control of drug-resistant tuberculosis. Tubercle Lung Dis 1995, 76:455-459.
6. WHO/IUATLD. Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis Drug Resistance in the World. Report No 3. Geneva: World Health Organization; 2004. WHO/HTM/TB/2004.343.
7. Javaid A., Hasan R., Zafar A., Ghafoor A., Pathan A.J., Rab A., et al. Prevalence of Primary multidrug resistance to anti-tuberculosis drugs in Pakistan. Int J Tuberc Lung Dis 2008, 12:326-331.
8. Bokhari A., Nizamani N.M., Jackson D.J., Rehan N.E., Rahman M., Muzaffar R. HIV risk in Karachi and Lahore, Pakistan: an emerging epidemic in injecting and commercial sex networks. Int J STD AIDS 2007, 18:486-492.
9. Taylor J.P., Sweat D.B., Suarez L. Epidemiology of Drug Resistant Tuberculosis in Texas. Am J Epidemiol 1999, 149:359-365.
10. Keane V.P., DeKlerk N., Krieng T. Risk factors for the development of non-response to first-line treatment for tuberculosis in Southern Vietnam. Int J Epidemiol 1997, 26:1115-1120.
11. Schwoebel V., Decludt B., Benoist A.C. Multidrug resistant tuberculosis in France 1992-94: Two case-control studies. BMJ 1998, 317:630-631.
12. Vernon A., Burman W., Benator D. Acquired rifampicin-mono-resistance in patients with HIV related tuberculosis treated with once-weekly rifampicin and isoniazid. Lancet 1999, 353:1843-1847.
13. Espinal M.A., Laserson K., Camacho M., Fusheng Z., Kim S.J., Tlali R.E. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001, 5:887-893.
14. Sandman L., Schluger N.W., Davidov A.L. Risk factors for Rifampicin-monoresistant Tuberculosis: A Case-Control Study. Am J Respir Crit Care Med 1999, 159:468-472.
15. Pablos-Mendez A., Raviglione M.C. Global Surveillance For Anti-Tuberculosis Drug Resistance, 1994-1997. N Engl J Med 1998, 338:1641-1649.
16. Nolte F.S., Metchock B. Mycobacterium. Manual of clinical microbiology 1999, American Society for Microbiology Press, Washington DC, pp. 400-37. 7th ed. P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds.).
17. Koneman E.W., Allen S.D., Janda W.M., Schereckenberger P.C. W.J. Color Atlas and Text Book of Microbiology 1997, Lippincott, Philadelphia New York. 5th ed.
18. Conde-Glez C.J. Analysis of herpes simplex virus 1 and 2 infection in women with high risk sexual behaviour in Mexico. Int J Epidemiol 1999, 8:571-576.
19. Sharma S.K., Mohan H. Multidrug-resistant tuberculosis. Indian J Med Res 2004, 120:354-376.
20. Tupasi T.E., Gupta R., Quelapio M.I., Orillaza R.B. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006, 3:e352.
21. Mdivani N., Zangaladze E., Volkova N., Kourbatova E., Jibuti T., Shubladze N., et al. High prevalence of multidrug-resistant tuberculosis in Georgia. Int J Infect Dis 2008, 12:635-644.
22. Atre S.R., Kudale A.M., Morankar S.N., Rangan S.G., Weiss M.G. Cultural concepts of tuberculosis and gender among the general population without tuberculosis in rural Maharashtra, India. Trop Med Int Health 2004, 9:1228-1238.
23. Atre Sachin R., Mistry N. Multidrug-Resistant tuberculosis (MDR-TB) in India: An attempt to link Biosocial Determinants. J Public Health Policy 2005, 26:96-114.
24. Alrajhi A.A., Abdulwahab S., Almodovar E., Al-Abdely H.M. Risk factors for drug-resistant Mycobacterium tuberculosis in Saudi Arabia. Saudi Med J 2002, 23:305-310.
25. Faustini A., Hall A.J., Perucci C.A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006, 61:158-163.
26. Espinal M.A., Baez J., Soriano G., Garcia V., Laszlo A., Reingold A.Lea Drug-resistant tuberculosis in the Dominican Republic: results of a nationwide survey. Int J Tuberc Lung Dis 1998, 2:490-498.
27. Johnson J.K., Bharadwaj R. Factors associated with drug resistance in pulmonary tuberculosis. Indian J Chest Dis Allied Sci 2003, 45:105-109.
28. Sharma S.K., Turaga K.K., Balamurugan A., Saha P.K., Pandey R.M., Jain NKea. Clinical and genetic risk factors for the development of multidrug-resistant tuberculosis in non-HIV infected at a tertiary care center in India: a case-control study. Infect Genet Evol 2003, 3:183-188.
29. Lerner B.H. From careless consumptives to recalcitrant patients: the historical construction of noncompliance. Soc Sci Med 1997, 45:1423-1431.
30. Driver C.R., Matus S.P., Bayuga S., Winters A.I., Munsiff S.S. Factors associated with tuberculosis treatment interruption in New York City. J Public Health Manage Pract 2005, 11:361-368.
31. WHO. Adherence to long term therapies: evidence for action. Geneva: World Health Organization; 2003. WHO/MNC/03.01.
32. Kass E.H. Infectious diseases and social change. J Infect Dis 1971, 123:110-114.
33. Dubos R., Dubos J. The white plague: tuberculosis, Man and Society 1987, Rutgers University Press, New Brunswick.
34. Spence D.S., Hotchkiss J., Williams C.S.D., Davies P.D.O. Tuberculosis and Poverty. BMJ 1993, 307:759-761.
35. AI Jarad N., Parastatides S., Paul E.A., Sheldon C.D., Gaya H. Characteristics of patients with drug resistance and drug sensitive TB in East London between 1984-1992. Thorax 1994, 49:808-810.
36. Murray J., Sonnenburg P., Shearer S., Godfrey-Faussett P. Drug-resistant pulmonary tuberculosis in a cohort of Southern African goldminers with high prevalence of HIV infection. S Afr med J 2000, 90:381-386.
37. Barroso E.C., Mota R.M.S., Santos R.O., Souza A.L.O., Barroso J.B., Rodrigues J.L.N. Risk factors for acquired multidrug-resistant tuberculosis. J Pneumol 2003, 29:89-97.
38. Natal S., Toledo A., Penha M., Velente J. Modelo de predicao para resistencia aos tuberculostaticos. J Pneumol 2000, 26:S23.